The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pretreatment serum mitochondrial DNA (mtDNA) correlates with shorter progression-free and overall survival in patients with advanced ovarian cancer (OC).
Kassondra S. Grzankowski
No relevant relationships to disclose
Anm Nazmul H. Khan
No relevant relationships to disclose
Kevin H. Eng
No relevant relationships to disclose
Melissa Grimm
No relevant relationships to disclose
Kelly L. Singel
No relevant relationships to disclose
Nonna Kolomeyevskaya
No relevant relationships to disclose
Kirsten B. Moysich
No relevant relationships to disclose
Kunle Odunsi
No relevant relationships to disclose
Brahm H. Segal
No relevant relationships to disclose